Analysts Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $8.50

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $8.50.

A number of research firms recently commented on XFOR. Guggenheim began coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 target price for the company. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Finally, Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of XFOR. Indivisible Partners acquired a new position in X4 Pharmaceuticals during the 4th quarter valued at approximately $40,000. SummitTX Capital L.P. acquired a new position in X4 Pharmaceuticals during the 1st quarter valued at approximately $46,000. Squarepoint Ops LLC acquired a new position in X4 Pharmaceuticals during the 4th quarter valued at approximately $50,000. Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the 3rd quarter valued at approximately $47,000. Finally, Stifel Financial Corp acquired a new position in X4 Pharmaceuticals during the 4th quarter valued at approximately $82,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $3.94 on Monday. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83. The firm has a 50 day moving average of $4.14 and a 200 day moving average of $3.86. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $371.62 million, a price-to-earnings ratio of -0.87 and a beta of 0.31.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The company had revenue of $2.71 million during the quarter, compared to analysts’ expectations of $3.20 million. As a group, sell-side analysts anticipate that X4 Pharmaceuticals will post -0.77 earnings per share for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.